Amphenol RF has introduced new non-magnetic SMPM bullet adapters into its extensive adapter portfolio. With its specially engineered design, this adapter is immune to interference from electromagnetic ...

Key to that mission is the “STEER” study, a late-stage trial of children with moderate SMA who are older than two years and have never before received certain targeted medicines like Zolgensma, Biogen ...

A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the treatment of older patients with spinal muscular atrophy (SMA).

NEW DELHI -- India is considering adopting Japan's next-generation bullet train for a high-speed rail project currently underway in the west, according to a source close to the Indian government.

The pivotal trial enrolled only babies under 6 months. Two-year-olds born with the most common and severe form of SMA would likely have lost too many neurons to benefit from the therapy.

OAV101 IT, a version of the gene therapy Zolgensma (onasemnogene abeparvovec-xioi) that’s administered into the spinal canal, can be safely given to people with spinal muscular atrophy (SMA) who were ...

Newly approved SMA therapies show promise but face global accessibility challenges, widening healthcare disparities due to high costs and limited availability. Newborn screening for SMA is ...

Amphenol RF is pleased to introduce new non-magnetic SMPM bullet adapters into our extensive adapter portfolio. With its specially-engineered design, this adapter is immune to interference from ...